Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Cardiac disorders – page 36

  • 481 clinical trials
  • 225 recruiting
  • 172 conditions
  • 28 countries

Conditions in this area

172 conditions with trials, the busiest first

Atrial fibrillation55Cardiac failure42Coronary artery disease37Acute myocardial infarction30Cardiac amyloidosis29Acute coronary syndrome21Cardiac arrest19Cardiac failure chronic17Cardiovascular disorder16Heart failure with reduced ejection fraction16Hypertrophic cardiomyopathy16Cardiac failure acute14Glycogen storage disease type II14Heart failure with preserved ejection fraction13Myocardial infarction13Cardiomyopathy11Myocardial ischaemia11Cardiogenic shock10Chronic coronary syndrome10Dilated cardiomyopathy9Myocarditis9Aortic valve stenosis7Chronic kidney disease6Trisomy 216+148

Clinical trials in Cardiac disorders

481 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

481 clinical trials

Cardiac ventricular thrombosis+1

Not recruiting

Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Acute myocardial infarction

Not recruiting

Study on Ticagrelor for Patients with Heart Attack After Coronary Stenting

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Vaestra Goetalandsregionen

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Atrial fibrillation+3

Not recruiting

Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Rijnstate Ziekenhuis Stichting

Cardiac failure chronic

Not recruiting

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azd5462
  • Sponsor:AstraZeneca AB

Prosthetic valve endocarditis

Not recruiting

Study on Gallium Citrate Ga-68 PET/CT for Diagnosing Prosthetic Valve Infective Endocarditis in Patients Suspected of Having the Condition

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium Citrate Ga-68
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Glycogen storage disease type II

Not recruiting

Study on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Myocarditis

Not recruiting

Study on the Effect of Cannabidiol (CardiolRx) on Heart Recovery in Patients with Acute Myocarditis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Cardiol Therapeutics Inc.

Coronary artery disease

Not recruiting

Study on Inclisiran and Statin Therapy for Patients with Non-obstructive Coronary Artery Disease to Assess Atherosclerotic Plaque Progression

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Glycogen storage disease type II

Not recruiting

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Substances studied in this area

The therapies tested most often in Cardiac disorders trials.

Acetylsalicylic Acid44 clinical trialsClopidogrel30 clinical trialsTicagrelor27 clinical trialsSodium Chloride25 clinical trialsDapagliflozin22 clinical trialsApixaban21 clinical trialsEmpagliflozin20 clinical trialsRivaroxaban19 clinical trialsPrasugrel18 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.